Maria Gisella Cavallo
Overview
Explore the profile of Maria Gisella Cavallo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barchetta I, Zampieri M, Cimini F, Dule S, Sentinelli F, Passarella G, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941038
Metabolic-associated steatotic liver disease (MASLD) represents the most common chronic hepatopathy worldwide and an independent risk factor for cardiovascular disease and mortality, particularly when liver fibrosis occurs. Epigenetic alterations, such...
2.
Barchetta I, Dule S, Cimini F, Sentinelli F, Oldani A, Passarella G, et al.
Diabetes Metab Res Rev
. 2024 Dec;
41(1):e70018.
PMID: 39655684
Context: The mechanisms underlying bone fragility and increased fracture risk observed in individuals with type 2 diabetes (T2D) are not yet fully elucidated. Previous research has suggested a role for...
3.
Totaro M, Barchetta I, Sentinelli F, Cimini F, Palazzi S, DAlessandro F, et al.
Front Endocrinol (Lausanne)
. 2024 Dec;
15:1476751.
PMID: 39640886
Background: Osteoporosis and metabolic syndrome (MetS) are conditions associated with ageing and chronic inflammation; among MetS' components, visceral obesity has been correlated to low bone mineral density in postmenopausal women....
4.
Zampieri M, Karpach K, Salerno G, Raguzzini A, Barchetta I, Cimini F, et al.
Redox Biol
. 2024 Jun;
75:103243.
PMID: 38906011
Background: Type 2 diabetes mellitus (T2DM) is characterized by disrupted glucose homeostasis and metabolic abnormalities, with oxidative stress and inflammation playing pivotal roles in its pathophysiology. Poly(ADP-ribosyl)ation (PARylation) is a...
5.
Lanzillotta C, Tramutola A, Lanzillotta S, Greco V, Pagnotta S, Sanchini C, et al.
Redox Biol
. 2024 Jun;
73:103221.
PMID: 38843768
Brain insulin resistance links the failure of energy metabolism with cognitive decline in both type 2 Diabetes Mellitus (T2D) and Alzheimer's disease (AD), although the molecular changes preceding overt brain...
6.
Barchetta I, Cavallo M
Atherosclerosis
. 2024 Mar;
392:117514.
PMID: 38503610
No abstract available.
7.
Maddaloni E, Naciu A, Mignogna C, Galiero R, Amendolara R, Fogolari M, et al.
Diabetes Obes Metab
. 2024 Feb;
26(5):1670-1677.
PMID: 38297915
Aim: To compare the efficacy and safety of saxagliptin/dapagliflozin and insulin glargine in people with latent autoimmune diabetes in adults (LADA). Methods: In this phase 2b multicentre, open-label, comparator-controlled, parallel-group,...
8.
Barchetta I, Cimini F, Sentinelli F, Chiappetta C, Di Cristofano C, Silecchia G, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139003
Lipopolysaccharide (LPS) and its binding protein LBP have emerged as potential contributors to the progression from overweight/obesity to overt metabolic diseases and NAFLD. While LPS is known to activate hepatocyte...
9.
Copetti M, Baroni M, Buzzetti R, Cavallo M, Cossu E, DAngelo P, et al.
Diabetes Metab Res Rev
. 2023 Oct;
40(2):e3734.
PMID: 37839040
Context: Mortality in type 2 diabetes is twice that of the normoglycemic population. Unravelling biomarkers that identify high-risk patients for referral to the most aggressive and costly prevention strategies is...
10.
Cimini F, Tramutola A, Barchetta I, Ceccarelli V, Gangitano E, Lanzillotta S, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108445
Biliverdin reductase-A (BVRA) is involved in the regulation of insulin signaling and the maintenance of glucose homeostasis. Previous research showed that BVRA alterations are associated with the aberrant activation of...